No Data
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.
HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.
PuraPharm Corp. Ltd. Announces Auditor Change
Hong Kong's Department of Health: To develop Hong Kong into a gateway for the internationalization of traditional Chinese medicine and Chinese herbal medicine.
Secretary for Food and Health of the Hong Kong Special Administrative Region, Dr. Constance Chan, stated that in order to promote the standardization and internationalization of traditional chinese medicine, Hong Kong aims to become a gateway for the internationalization of traditional chinese medicine.
Purapharm collaborates with EC Healthcare to hold a 'Pink October' charity clinic, promoting the innovation of integrated Chinese and Western medical models.
Hong Kong, 7th November 2024 / PRNewswire / - Purapharm Group (1498.HK) and EC Healthcare (2138.HK) jointly organized the "Pink October: Integrating East and West, Breast Cancer Prevention Charity Event" in October, providing professional consultation services combining traditional Chinese medicine and Western medicine for breast cancer and other cancer patients. This event is not only an important milestone in the initiation of strategic cooperation between the two parties, but also a innovative move to promote the development of collaboration between traditional Chinese medicine and Western medicine, and to advance the modernization of traditional Chinese medicine. The event has received support from the Global Chinese Breast Cancer Organizations Alliance, Hong Kong Nurses Association, Alone_In_This_War Foundation and Hong Kong Academy of Nursing among many others.
PuraPharm Corp. Plans Major Capital Restructuring
